

# Human IL-1 $\beta$ Monoclonal Antibody

Catalog No.: YR0006

## Basic Information

### Molecular Weight

150 kDa

### Endotoxin

<1EU/mg (<0.001EU/ $\mu$ g) Determined by LAL gel clotting assay

### Sterility

0.2  $\mu$ m filtration

### Aggregation

<5% Determined by SECP

### Purity

>95% Determined by SDS-PAGE

## Background

Canakinumab is a recombinant human monoclonal antibody which binds to IL-1 $\beta$  (interleukin-1 beta). It's mode of action is based on the neutralization of IL-1 $\beta$  signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. In June 2009, the FDA approved canakinumab for the treatment of cryopyrin-associated periodic syndromes (CAPS), a spectrum of autoinflammatory syndromes. In September 2016, the FDA approved it's use for three additional rare and serious auto-inflammatory diseases: tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD), and familial Mediterranean fever (FMF). In June 2020, canakinumab was FDA-approved for the indication to treat active Still's disease, including adult-onset Still's disease (AOSD).

## Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

## Immunogen Information

### Clone

Canakinumab Biosimilar

### Isotype

Human IgG1 kappa

### Immunogen

### Recommended Isotype Control(s)

### Recommended Dilution Buffer

1xPBS pH 7.3

## Contact

☎ | 400-999-6126

✉ | [cn.market@abclonal.com.cn](mailto:cn.market@abclonal.com.cn)

🌐 | [www.abclonal.com.cn](http://www.abclonal.com.cn)

## Product Information

### Production


Purified from cell culture supernatant in an animal-free facility

### Purification


Protein A or G purification

### Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)



Direct ELISA binding curve demonstrating the recognition of Human Anti-Human IL-1 $\beta$  (Research Grade Canakinumab Biosimilar) Monoclonal Antibody to IL-1 $\beta$ . The target protein was coated onto the microplate well surface, followed by binding of the antibody. A donkey anti-human IgG HRP conjugate was used for detection.



Human IL-1 $\beta$  SPR assay. Determined through SPR assay, the Human Anti-Human IL-1 $\beta$  (Research Grade Canakinumab Biosimilar) Monoclonal Antibody is capable of binding to Human IL-1 $\beta$  with an affinity constant of 0.1067 nM.